Sebacoyl Dinalbuphine Ester
Phase 3Small molecule
Sebacoyl Dinalbuphine Ester is one of 56 small molecule programs targeting Cesarean Section. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
83 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Dynastat
PfizerPreclinical
Proamatine
TakedaPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemorrhoid1 trial
Cesarean Section1 trial
Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section
Recruiting·—·Phase 2/3·NCT06344169·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sebacoyl Dinalbuphine Ester. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLumosa Therapeutics Co., Ltd.